- Home
- FDMT
as 11-08-2024 11:34am EST
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 420.7M | IPO Year: | 2020 |
| Target Price: | $46.88 | AVG Volume (30 days): | 660.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.90 - $36.25 | Next Earning Date: | 11-15-2024 |
| Revenue: | $20,218,000 | Revenue Growth: | 784.81% |
| Revenue Growth (this year): | -70.79% | Revenue Growth (next year): | 57.85% |
Stock Insider Trading Activity of 4D Molecular Therapeutics Inc. (FDMT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bizily Scott | FDMT | Chief Legal Officer | Sep 16 '24 | Sell | $16.33 | 500 | $8,165.00 | 6,781 | |
| Bizily Scott | FDMT | Chief Legal Officer | Aug 19 '24 | Sell | $15.00 | 500 | $7,500.00 | 6,781 |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
Zacks
25 days ago
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
Zacks
a month ago
4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
GlobeNewswire
2 months ago
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
MT Newswires
2 months ago
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics to Neutral From Overweight
Benzinga
2 months ago
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
BioPharma Dive
2 months ago
4D Molecular data ‘bode well’ for eye gene therapy, but shares fall
MT Newswires
2 months ago
Chardan Lifts Price Target on 4D Molecular Therapeutics to $39 From $38, Keeps Buy Rating
Compare FDMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.